Todos Medical - Full Color Logo
  • R&D Pipeline
    • Proprietary Diagnostics
      • Videssa® Breast: Cancer Blood Test
      • LymPro™: Alzheimer's Blood Test
      • TolloTest™: Coronavirus 3CL Protease Test
      • TBIA: AI Cancer Platform
    • Antiviral Drug Development
      • Tollovir™: 3CL Protease Inhibitor
  • Products & Services
    • Lab Solutions
      • Provista Diagnostics: CLIA/CAP Lab
      • COVID Testing: Lab Supplies & Automated Solutions
    • Dietary Supplement
      • Tollovid™: 3CL Protease Inhibitor
  • Insights
    • Publications
    • News & Media
    • Downloads
    • How It Works: 3CL Protease Inhibitors
    • Case Study: Lab Automation
  • Investors
  • About
    • Management Team
    • Board of Directors
    • Advisors
    • Career Opportunities
    Add a button link here
    Contact Us

    Press Releases

    Investors

    Investors

    • Overview
    • News & Events
      • Press Releases
      • IR Calendar
      • Email Alerts
    • Company Info
      • Management Team
      • Presentations
      • Contacts
      • FAQ
    • Financial Info
      • Financial Results
      • Income Statement
      • Balance Sheet
      • Cash Flow
    • Stock Data
      • Quote
      • Charts
      • Historical Data
    • SEC Filings
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Governance
      • Board of Directors
      • Governance Documents
    • News & Events

    • Press Releases
    • IR Calendar
    • Email Alerts
    Aug 23, 2022 9:14am EDT

    Todos Medical Initiates MonkeyPox Diagnostic Case Studies After Being Approached by 4 Patients, Including 3 Women

    Aug 22, 2022 9:40pm EDT

    Todos Medical Reports Second Quarter 2022 Financial Results and Business Update Conference Call on Tuesday, August 23 at 8:30am ET

    Aug 19, 2022 8:30am EDT

    Todos Medical Announces Preprint of Data from First 100 Participants in IRB-waived Market Research Study of Supplementation with Tollovid in Long COVID

    Aug 15, 2022 9:48am EDT

    Todos Medical Reports Pre-Print of Publication Detailing Tollovid Supplementation Following COVID-19 mRNA Vaccination in Long COVID

    Aug 11, 2022 9:07am EDT

    Todos Medical Completes Trial Design for Tollovid™ Long COVID Clinical Study in Adults

    Aug 10, 2022 9:11am EDT

    Todos Medical Announces PCR Validation of Wound and Respiratory Pathogen Panels at CLIA/CAP Lab Provista Diagnostics

    Aug 08, 2022 7:25am EDT

    Todos Medical Announces First Two Contracts for PCR-based MonkeyPox Testing at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics

    Aug 05, 2022 1:49pm EDT

    Todos Medical Announces First Long COVID Clinic Laboratory Services Agreement for Long COVID Panel Biomarker Partnership with Amerimmune Diagnostics

    Aug 03, 2022 7:52am EDT

    Todos Medical Initiates Validation Plan for PCR-based MonkeyPox Test at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics

    Aug 01, 2022 9:56am EDT

    Todos Medical Announces Preprint of Acute COVID-19 Paxlovid Rebound Rescued by Tollovid

    • arrow_back
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • …25
    • arrow_forward
    rss_feed News RSS
    • Email Alerts
    • Company Profile
    • Contacts
    • RSS News Feed

    Todos Medical - Full Color-1

     

    About Us

    Todos Medical Ltd. is an in vitro diagnostics company focused on the development of novel blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer’s Disease, and the distribution of comprehensive solutions for COVID-19 screening.

    OTCQB: TOMDF

    Contact Us

    Todos Medical Ltd.
    121 Derech Menachem Begin

    30th Floor
    Tel Aviv, Israel 6701203
    Phone: +972-73-207-7259

    Todos Medical U.S.A.
    40 Wall Street, Suite 2702

    New York, NY 10005
    Phone: +1-917-983-4229

    Sign Up

    Follow us on Twitter Follow us on Facebook Follow us on LinkedIn
    © 2023 Todos Medical. All rights reserved.